Loading...
XNASNTRA
Market cap21bUSD
Dec 23, Last price  
161.99USD
1D
0.07%
1Q
31.61%
Jan 2017
1,283.35%
IPO
636.32%
Name

Natera Inc

Chart & Performance

D1W1MN
XNAS:NTRA chart
P/E
P/S
19.75
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
14.73%
Rev. gr., 5y
33.26%
Revenues
1.08b
+31.99%
14,250,00055,171,000159,289,000190,355,000217,074,000210,939,000257,654,000302,328,000391,005,000625,486,000820,222,0001,082,571,000
Net income
-435m
L-20.63%
-76,171,000-37,110,000-5,152,000-70,275,000-95,765,000-136,314,000-128,154,000-124,827,000-229,743,000-471,716,000-547,799,000-434,801,000
CFO
-247m
L-42.77%
-14,905,000-24,132,00010,490,000-37,832,000-73,902,000-96,792,000-70,581,000-63,444,000-182,512,000-335,236,000-431,501,000-246,955,000
Earnings
Feb 26, 2025

Profile

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
IPO date
Jul 02, 2015
Employees
2,958
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,082,571
31.99%
820,222
31.13%
625,486
59.97%
Cost of revenue
910,509
772,671
582,626
Unusual Expense (Income)
NOPBT
172,062
47,551
42,860
NOPBT Margin
15.89%
5.80%
6.85%
Operating Taxes
271
978
618
Tax Rate
0.16%
2.06%
1.44%
NOPAT
171,791
46,573
42,242
Net income
(434,801)
-20.63%
(547,799)
16.13%
(471,716)
105.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
235,441
446,229
564,372
BB yield
-3.27%
-11.29%
-6.67%
Debt
Debt current
92,023
80,350
50,052
Long-term debt
416,995
434,807
402,466
Deferred revenue
19,128
20,001
21,318
Other long-term liabilities
(20,078)
(14,394)
Net debt
(369,959)
(383,149)
(443,591)
Cash flow
Cash from operating activities
(246,955)
(431,501)
(335,236)
CAPEX
(39,199)
(47,697)
(41,030)
Cash from investing activities
168,498
330,338
(205,193)
Cash from financing activities
254,461
482,640
576,188
FCF
83,595
(66,777)
(37,264)
Balance
Cash
878,977
898,306
914,282
Long term investments
(18,173)
Excess cash
824,848
857,295
864,835
Stockholders' equity
(2,380,510)
(1,958,986)
(1,397,113)
Invested Capital
3,606,958
3,098,914
2,446,593
ROIC
5.12%
1.68%
2.05%
ROCE
14.03%
4.10%
4.02%
EV
Common stock shares outstanding
114,997
98,408
90,558
Price
62.64
55.94%
40.17
-56.99%
93.39
-6.16%
Market cap
7,203,412
82.22%
3,953,049
-53.26%
8,457,212
4.90%
EV
6,833,453
3,569,900
8,013,621
EBITDA
196,159
64,253
54,114
EV/EBITDA
34.84
55.56
148.09
Interest
12,638
9,319
8,305
Interest/NOPBT
7.35%
19.60%
19.38%